Matthew C. Kiernan

Matthew C. Kiernan

MBBS, PhD, DSc, FRACP

Neurologist

Over 30 years of professional experience

Male📍 Randwick

About of Matthew C. Kiernan

Matthew C. Kiernan is a neurologist based at 139 Barker Street, Randwick, NSW 2031. Neurology can feel like a lot to take in, especially when symptoms come on suddenly or slowly over time. Matthew works with people who need clear answers about what’s going on, and practical next steps for care.


He looks after adults and also some patients in the wider neurology space, including people dealing with long-term nerve and muscle problems. Common reasons people see him include symptoms from motor neuron conditions, ongoing muscle weakness, and issues where the nerves don’t work the way they should. He also helps with peripheral nerve problems like neuropathy, including cases linked to diabetes or other health issues.


Memory and thinking changes are another big part of his work. This can include dementia, frontotemporal dementia, and other conditions where brain function is affected. At times, patients also come in for movement disorders such as Parkinson’s disease, essential tremor, and other ongoing changes in movement.


Some patients are managing conditions that affect the brain, spinal cord, and nerves more broadly. For example, multiple sclerosis, stroke-related problems, and other neurological illnesses that can change over time. There are also cases involving abnormal sensations, muscle tightness, spasticity, and cramping-fasciculation type symptoms.


Matthew has over 30 years of professional experience. His training and qualifications span both general medical education and specialised neurology. He completed his MBBS with Honours at the University of Sydney in 1989, then went on to neurology residency at the same university. He later completed a PhD in Neurology through UNSW, followed by FRACP through the Royal Australasian College of Physicians.


He also holds a Doctor of Science (DSc) in Neuroscience from UNSW, completed in 2010. With that background, he keeps up with new thinking in brain and nerve care, and he has a research focus as part of his career.


Where appropriate, Matthew may discuss clinical trials as an option. This is especially relevant for some ongoing neurological conditions, when patients are looking for more than standard treatment. The aim is simple: make sure care decisions are based on what’s most helpful for each person’s situation.

Education

  • MBBS - Bachelor of Medicine, Bachelor of Surgery (Honours), University of Sydney,1989
  • MBBS, Neurology Residency Program, University of Sydney, 1989
  • PhD - Doctor of Philosophy – Neurology, UNSWUNSW 1996
  • FRACP - Medicine & Neurology, Royal Australasian College of Physicians ,1997
  • DSc - Doctor of Science - Neuroscience, UNSWUNSW, 2010

Services & Conditions Treated

Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease)Primary Lateral SclerosisChronic Inflammatory Demyelinating PolyneuropathyChronic PolyradiculoneuritisContinuous Muscle Fiber Activity HereditaryDementiaFrontotemporal DementiaIsaacs' SyndromeMultifocal Motor NeuropathyNeurotoxicity SyndromesPeripheral NeuropathyRiboflavin Transporter Deficiency NeuronopathyAccessory Deep Peroneal NerveCramp-Fasciculation SyndromeDevelopmental Dysphasia FamilialHereditary Spastic ParaparesisMononeuritis MultiplexSpinal and Bulbar Muscular AtrophySpinal Muscular Atrophy (SMA)Spinal Muscular Atrophy Type 2Spinal Muscular Atrophy Type 3Acute Cerebellar AtaxiaAlzheimer's DiseaseBrown SyndromeCACH SyndromeCardiac AmyloidosisCarpal Tunnel SyndromeCerebrotendinous XanthomatosisCharcot-Marie-Tooth DiseaseChronic Kidney DiseaseCorticobasal DegenerationCryoglobulinemiaDiabetic NeuropathyDrug Induced DyskinesiaDysarthriaEncephalitisEnd-Stage Renal Disease (ESRD)Essential TremorFaintingFamilial DysautonomiaFamilial Transthyretin AmyloidosisFoot DropGastrostomyGuillain-Barre SyndromeHearing LossHigh Potassium LevelHyperventilationInclusion Body MyositisLeigh SyndromeLewy Body Dementia (LBD)Low Blood PressureMovement DisordersMultiple Sclerosis (MS)Muscle AtrophyObesityOlivopontocerebellar AtrophyParaplegiaParkinson's DiseasePorphyriaPrimary AmyloidosisPrimary Progressive AphasiaProgressive Multifocal LeukoencephalopathyPseudobulbar AffectSepsisSpastic ParaparesisSpastic Paraplegia Type 2Spastic Paraplegia Type 7SpasticitySpinal Muscular Atrophy Type 1Spinocerebellar AtaxiaSpinocerebellar Ataxia Type 8Stiff Person SyndromeStriatonigral Degeneration InfantileStrokeTransthyretin AmyloidosisType 1 Diabetes (T1D)Type 2 Diabetes (T2D)Wallerian DegenerationXanthoma

Publications

5 total
Utility of the Gold Coast criteria for amyotrophic lateral sclerosis: Experience with fast progressors.

Journal of the neurological sciences • January 30, 2025

Matthew Kiernan, Hannah Timmins

In the absence of a definitive diagnostic test for amyotrophic lateral sclerosis (ALS), various criteria have been developed by those working in the field, particularly over recent decades [1]. These criteria were typically clinically based, and described features indicative of upper and lower motor neurone disease involvement, as identified by Charcot [3]. This sustained and iterative process has culminated in consensus approaches, as promoted by the World Federation of Neurology (WFN), initially with the El Escorial criteria, later revised, and with subsequent incorporation of technological advance, particularly in the realm of clinical neurophysiology [2]. Each of these more recent criteria incorporated degrees of certainty: possible, probable or definite disease. However, a considerable proportion of patients labelled as ‘possible ALS’ ultimately succumb to the disease without ever meeting the criteria for more definitive diagnostic categories. Furthermore, these classifications often led to misunderstandings among both patients and clinicians, being mistakenly perceived as an assessment of ALS likelihood rather than a structured diagnostic framework [18]. In contrast, the most recent WFN consensus, the Gold Coast criteria, removed diagnostic uncertainty, in part to lower barriers for patient enrolment to clinical trials [16]. Now the diagnosis is ALS, or it isn't, based on the supportive information, including clinical investigations, typically used to rule out other conditions. Having established consensus criteria, it was important for validation studies, which have overwhelmingly supported a more streamlined diagnostic process, and clinical outcome [11]. In further support, a study in the current issue of Journal of Neurological Sciences has confirmed the superiority of the Gold Coast criteria when assessing ALS patients with a fast disease progression, while at the same time further validating the criteria in a further cohort of Japanese patients [13].

An Annotated Multi-Site and Multi-Contrast Magnetic Resonance Imaging Dataset for the study of the Human Tongue Musculature.

Scientific data • January 15, 2025

Fernanda Ribeiro, Xiangyun Zhu, Xincheng Ye, Sicong Tu, Shyuan Ngo, Robert Henderson, Frederik Steyn, Matthew Kiernan, Markus Barth, Steffen Bollmann, Thomas Shaw

This dataset provides the first annotated, openly available MRI-based imaging dataset for investigations of tongue musculature, including multi-contrast and multi-site MRI data from non-disease participants. The present dataset includes 47 participants collated from three studies: BeLong (four participants; T2-weighted images), EATT4MND (19 participants; T2-weighted images), and BMC (24 participants; T1-weighted images). We provide manually corrected segmentations of five key tongue muscles: the superior longitudinal, combined transverse/vertical, genioglossus, and inferior longitudinal muscles. Other phenotypic measures, including age, sex, weight, height, and tongue muscle volume, are also available for use. This dataset will benefit researchers across domains interested in the structure and function of the tongue in health and disease. For instance, researchers can use this data to train new machine learning models for tongue segmentation, which can be leveraged for segmentation and tracking of different tongue muscles engaged in speech formation in health and disease. Altogether, this dataset provides the means to the scientific community for investigation of the intricate tongue musculature and its role in physiological processes and speech production.

The Neonatal Microbiome: Implications for Amyotrophic Lateral Sclerosis and Other Neurodegenerations.

Brain Sciences • January 13, 2025

Andrew Eisen, Matthew Kiernan

Most brain development occurs in the "first 1000 days", a critical period from conception to a child's second birthday. Critical brain processes that occur during this time include synaptogenesis, myelination, neural pruning, and the formation of functioning neuronal circuits. Perturbations during the first 1000 days likely contribute to later-life neurodegenerative disease, including sporadic amyotrophic lateral sclerosis (ALS). Neurodevelopment is determined by many events, including the maturation and colonization of the infant microbiome and its metabolites, specifically neurotransmitters, immune modulators, vitamins, and short-chain fatty acids. Successful microbiome maturation and gut-brain axis function depend on maternal factors (stress and exposure to toxins during pregnancy), mode of delivery, quality of the postnatal environment, diet after weaning from breast milk, and nutritional deficiencies. While the neonatal microbiome is highly plastic, it remains prone to dysbiosis which, once established, may persist into adulthood, thereby inducing the development of chronic inflammation and abnormal excitatory/inhibitory balance, resulting in neural excitation. Both are recognized as key pathophysiological processes in the development of ALS.

The comparative effect of propolis and chlorhexidine mouthwash on oral nitrite-producing bacteria and blood pressure regulation.

Journal of oral microbiology • December 18, 2024

R Bescos, L Du Toit, A Redondo Rio, P Warburton, T Nicholas, M Kiernan, R Burton, L Belfield, G Montagut, A Benavente, W Vevers, T Gabaldón, Z Brookes, P Casas Agustench

Propolis mouthwash (PROP-M) has demonstrated antibacterial properties like those of chlorhexidine mouthwash (CHX-M). However, its impact on the abundance of oral nitrite-producing species (NPS) and nitrite-producing activity (NPA) remains unexplored. Forty-five healthy individuals were randomised into 2 groups to rinse their mouth twice a day for seven days with either CHX-M (n = 21) or PROP-M (n = 24). Metagenomic sequencing (16S rRNA) was performed on saliva samples collected before and after each treatment. Additionally, salivary biomarkers and blood pressure were measured. CHX-M increased the relative abundance of NPS (p < 0.001) but significantly impaired the NPA (p < 0.001) compared to baseline and PROP-M. No significant differences in the relative abundance of NPS and NPA were observed in the PROP-M group. However, a significant increase of plasma nitrate (+7 µmol/L, p = 0.047) and a decrease in systolic BP (-2 mmHg, p = 0.022) was observed in this group compared to the baseline. The results indicate that PROP-M had a smaller effect on the abundance of NPS and NPA compared to CHX-M. Additionally, PROP-M reduced blood pressure in healthy individuals, but this effect was not associated with changes in the oral microbiome.

Post-infectious acute cerebellar ataxia in a young adult.

BMJ case reports • January 27, 2025

Tal Koren, Matthew Kiernan

Acute cerebellar ataxia is a clinical syndrome that involves loss of balance and coordination, typically within less than 72 hours. It usually presents in children and rarely affect adults. A woman in her early 20s presented with acute onset dizziness, vertigo, truncal ataxia and dysarthria 2 weeks following an acute viral illness. Cerebral MRI identified evidence of dural enhancement, and positron emission topography brain imaging showed cortical reduction of glucose metabolism, consistent with an encephalopathic process. Lumbar puncture established a normal cerebrospinal fluid protein and glucose, with seven white cells ×106/L. Subsequent investigations identified evidence of a recent Epstein-Bar virus, in keeping with a post-infectious acute cerebellar ataxia syndrome. Following treatment with intravenous methylprednisolone, symptoms resolved gradually over months. While post-infectious acute cerebellar ataxia is rare in adults, it is an important cause of an acute presentation of ataxia that should be recognised by paediatric and adult physicians.

Clinical Trials

2 total

Randomised Double-Blind Placebo-Controlled Phase 3 Trial of Triumeq in Amyotrophic Lateral Sclerosis

Active_not_recruitingPhase 3Dolutegravir, Abacavir and Lamivudine

To determine if Triumeq improves survival in Amyotrophic Lateral Sclerosis (ALS) compared with placebo

Participants: 390

Phase 2a Open Label Study, Safety and Tolerability of Combination Antiretroviral Therapy (Triumeq) in Participants With Amyotrophic Lateral Sclerosis (ALS) - The Lighthouse Project.

CompletedPhase 2

This is a phase 2a open label, multicentre design study to investigate the safety of Triumeq in patients with ALS at 24 weeks post treatment. In this phase 2a study the investigators aim to determine whether a combination of anti-retroviral therapy, Triumeq (dolutegravir 50mg, abacavir 600mg, lamivudine 300mg) is tolerated and safe in patients with ALS. As secondary outcomes, ALSFRS-R, ALSQOL, physical examination, neurophysical parameters and respiratory and muscle function will be evaluated. Blood and urine samples will be stored for possible future analysis for viral activity. Subjects will be screened for the study after signing an approved Informed consent document.

Participants: 43

Frequently Asked Questions

What services does Dr Matthew C. Kiernan offer?
Dr Kiernan provides neurological care with a focus on a wide range of conditions including motor and neurodegenerative disorders, neuropathies, movement disorders, dementia and related syndromes. Examples from his listed services include ALS, dementia (including frontotemporal dementia), multiple types of neuropathy, Parkinson's disease, multiple sclerosis, spinocerebellar ataxia, and various related neurological conditions.
What conditions does he commonly treat?
He treats conditions across the spectrum of neurology, such as motor neuron diseases, cognitive disorders, movement disorders, neuropathies, ataxias, and other neurological syndromes listed in his services. If you’re unsure whether your condition fits, it’s best to book a consult to discuss your symptoms.
How do I book an appointment with Dr Kiernan and where is the clinic located?
Appointments are available at his Randwick practice, located at 139 Barker Street, Randwick, NSW 2031, Australia.
What should I bring to my first appointment?
Bring any relevant medical records, imaging or test results related to your neurological symptoms, a list of medications you’re taking, and details about your symptoms, including onset and progression. If you have a caregiver or family member who helps you, they can attend too.
What can I expect during an initial consultation?
During the first visit, Dr Kiernan will review your medical history, discuss your neurological symptoms, and may arrange appropriate tests or follow-up plans based on his evaluation. The focus is on understanding your concerns and outlining a clear plan.
Is Dr Kiernan’s practice able to manage complex or rare neurological conditions?
Yes. With over 30 years of experience and a broad range of neurological services, his practice aims to support patients with both common and complex neurological conditions.